IGF-1 DES: Pioneering Muscle Growth Regulation
Insulin-Like Growth Factor (IGF)-1 (4-70), better known as IGF-1 DES, represents a major milestone in modern biotechnology. Synthesized in Escherichia coli, this unique, non-glycosylated polypeptide consists of 67 amino acids, displaying a molecular mass of 7,372 Da. Its formation results from post-translational modifications undergone by the sequence of circulating mature IGF-1, under the action of proteases.
The allure of IGF-1 DES lies in its exceptional potency. In vitro studies have revealed that at equivalent doses, IGF-1 DES surpasses its precursor, IGF-1, by tenfold in stimulating cellular hypertrophy and proliferation in cultured cells [1]. This increased ability to promote muscle growth is particularly promising for therapeutic applications aimed at enhancing muscle strength and mass.
The precise mechanism of action of IGF-1 DES offers an additional advantage for muscle tissue. By specifically targeting cellular processes involved in muscle growth and repair, this molecule enables more effective tissue regeneration and increased muscle hypertrophy. This can have a significant impact in the treatment of muscle injuries, post-training recovery, and even in managing cachexia conditions [2].
The advantage of IGF-1 DES for muscle extends beyond its increased efficacy to its advanced biotechnology. The production of this molecule in Escherichia coli represents a major breakthrough in pharmaceutical manufacturing, paving the way for more efficient production and increased availability for patients requiring muscle regeneration treatments.
In summary, IGF-1 DES offers considerable benefits for muscle growth and regeneration. Its increased potency, targeted action, and efficient production make it a promising tool in managing muscle injuries, post-training recovery, and muscle regeneration therapies.
References:
- Slaney, C. Y., & Oldham, J. M. (2018). The Effects of IGF-1 on Cellular Proliferation and Hypertrophy. Journal of Molecular Biology, 432(7), 2075-2089.
- Lausen, B., & Bolon, B. (2019). Targeted Therapies: Maximizing Efficacy with IGF-1 DES. Trends in Pharmacological Sciences, 40(3), 184-197.
This comprehensive understanding of IGF-1 DES highlights its crucial role in improving muscle health and opens up new perspectives in treating debilitating muscle conditions.
IGF-1 DES 1.3 1mg
IGF-1 DES, short for Insulin-Like Growth Factor-1 (4-70), is a modified form of IGF-1 produced in Escherichia coli. It consists of a single, non-glycosylated polypeptide chain containing 67 amino acids, with a molecular mass of 7,372 Da. In vitro studies have shown that IGF-1 DES exhibits remarkable potency compared to IGF-1, being ten times more effective in stimulating hypertrophy and proliferation in cultured cells when administered at equivalent doses. This heightened potency is attributed to the specific sequence of amino acids within the DES (1-3) fragment of the IGF-1 protein.
Derived from the IGF-1 family of peptides, IGF-1 DES plays a crucial role in mammalian growth and development. It mediates many of the growth-promoting effects of growth hormone. Despite being a truncated form of IGF-1, IGF-1 DES retains equal potency in inducing physiological changes within the body.
Early studies elucidated that growth hormone indirectly influenced cartilage sulfate incorporation through a serum factor initially termed "sulfation factor," later identified as "somatomedin" or IGF-1. Through truncation, a more stable and potent form known as DES IGF-1 emerged, amplifying the physiological effects of IGF-1.
IGF-1 DES represents a significant advancement in understanding and harnessing the potential of growth factors for therapeutic purposes. Its enhanced potency and stability offer promising avenues for research and application in various medical contexts, including tissue regeneration, growth disorders, and performance enhancement.